The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | An update on ASTRAL-3: guadecitabine vs treatment of choice in adults with previously treated MDS
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the results of the Phase III ASTRAL-3 trial comparing guadecitabine versus treatment of choice in adults with myelodysplastic syndromes (MDS) previously treated with hypomethylating agents (HMAs) (NCT02907359). Despite promising pre-clinical efficacy, the study did not report a significant improvement in overall survival (OS) for patients treated with guadecitabine. Dr Garcia Manero explains that this study should be used to improve the design of new Phase III studies in this patient population. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
